SGX-listed Singapore eDevelopment Limited’s (SeD; SGX:40V) wholly-owned subsidiary Impact Biomedical Inc. (“Impact”), announced today the initiation of Quantum, their research…
Browsing: Singapore eDevelopment Ltd
Singapore eDevelopment Limited’s (SeD; SGX:40V) wholly owned subsidiary Impact Biomedical Inc. has announced proven in vitro success with Equivir and…
SGX-listed Singapore eDevelopment Limited’s (SeD; SGX:40V) wholly owned subsidiary Impact Biomedical Inc. (“Impact Biomedical”) announced today that their COVID-19 research…
SGX-listed Singapore eDevelopment Limited’s (the “Company”) (SeD; SGX:40V) wholly owned subsidiary, Impact Biomedical Inc. (“Impact Biomedical”), would like to update…
SGX-listed Singapore eDevelopment Ltd’s (SeD; SGX:40V) wholly owned subsidiary Impact Biomedical Inc., announced today that their suite of antiviral and…
Singapore Exchange-listed Singapore eDevelopment Limited (Stock Code 40V) (“SeD”) wishes to announce today that its U.S. biomedical subsidiary, Global BioLife…
SINGAPORE – (ACN Newswire) – Singapore Exchange-listed Singapore eDevelopment Limited (Stock Code 40V) (“SeD”) wishes to announce today that its…